GILD34 Stock Price and Chart — BMFBOVESPA:GILD34

Key facts today

Gilead Sciences is set to announce a deal with the U.S. government to reduce some prescription drug prices, part of a larger initiative with major pharma firms.

Gilead Sciences has temporarily waived rights in a 10-year deal with Galapagos, enabling Galapagos to pursue external partnerships for its autoimmune treatment GLPG3667.

Gilead Sciences has appointed Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance.

Analyze the impact Analyze the impact

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Check out other big names from the same industry as GILD34.